Ono Makiko, Tsuda Hitoshi, Yunokawa Mayu, Yonemori Kan, Shimizu Chikako, Tamura Kenji, Kinoshita Takayuki, Fujiwara Yasuhiro
Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan,
Breast Cancer. 2015 Mar;22(2):141-52. doi: 10.1007/s12282-013-0464-4. Epub 2013 Apr 13.
The criteria for classifying hormone receptor (HR)-positive/HER2-negative breast cancers into low-risk and high-risk subgroups remain undetermined. Supportive data for optimal criteria to identify tumors in the high-risk subgroup are necessary for Japanese patients with HR-positive/HER2-negative breast cancers.
Using immunohistochemistry and fluorescence in situ hybridization, we identified 369 consecutive patients with HR-positive/HER2-negative, node-negative invasive breast cancers. We examined the prognostic impact of the Ki-67 labeling index (LI) based on 3 cutoff values, 10, 14, and 20 %, along with that of histological grade (HG) and nuclear grade (NG) by Cox's univariate and multivariate analyses.
The univariate analyses clearly showed that Ki-67 LI with any cutoff value divided the patients into distinct high-risk and low-risk groups, and that HG and NG were also powerful prognostic indicators. High Ki-67 LI with any cutoff value was strongly correlated with HG and NG, and when these parameters were included in the multivariate analyses, the impact of HG/NG was stronger than Ki-67 LIs. When the 10 % cutoff value was adopted, discordance between Ki-67 LI and grades was frequent in papillotubular-type invasive ductal carcinoma, predominantly intraductal carcinoma, and mucinous carcinoma.
Any of the Ki-67 LI values, regardless of cutoff value, could be applicable for the classification of high-risk and low-risk HR-positive/HER2-negative, node-negative invasive breast cancers. Luminal A/B subtyping according to Ki-67 LI, or HG/NG, in combination with histological type, appeared to be able to create an optimum risk estimation system for patients with HR-positive/HER2-negative, node-negative invasive breast cancers in Japan.
激素受体(HR)阳性/人表皮生长因子受体2(HER2)阴性乳腺癌分为低风险和高风险亚组的标准尚未确定。对于日本HR阳性/HER2阴性乳腺癌患者而言,确定用于识别高风险亚组肿瘤的最佳标准的支持性数据很有必要。
我们使用免疫组织化学和荧光原位杂交技术,确定了369例连续的HR阳性/HER2阴性、无淋巴结转移的浸润性乳腺癌患者。我们通过Cox单因素和多因素分析,研究了基于10%、14%和20%这三个临界值的Ki-67标记指数(LI)以及组织学分级(HG)和核分级(NG)的预后影响。
单因素分析清楚地表明,任何临界值的Ki-67 LI都能将患者分为明显的高风险和低风险组,并且HG和NG也是强大的预后指标。任何临界值的高Ki-67 LI都与HG和NG密切相关,当这些参数纳入多因素分析时,HG/NG的影响比Ki-67 LI更强。当采用10%的临界值时,在乳头管状型浸润性导管癌、主要为导管内癌和黏液癌中,Ki-67 LI与分级之间的不一致很常见。
无论临界值如何,任何Ki-67 LI值都可用于HR阳性/HER2阴性、无淋巴结转移的浸润性乳腺癌的高风险和低风险分类。根据Ki-67 LI或HG/NG,并结合组织学类型进行管腔A/B亚型分类,似乎能够为日本HR阳性/HER2阴性、无淋巴结转移的浸润性乳腺癌患者建立一个最佳的风险评估系统。